

Review Article



Disadvantages of Complete No. 10 Lymph Node Dissection in Gastric Cancer and the Possibility of Spleen-Preserving Dissection: Review

Tetsuro Toriumi , Masanori Terashima

Division of Gastric Surgery, Shizuoka Cancer Center, Shizuoka, Japan

OPEN ACCESS

Received: Aug 16, 2019

Accepted: Jan 17, 2020

Correspondence to

Masanori Terashima

Division of Gastric Surgery, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan.
E-mail: m.terashima@scchr.jp

Copyright © 2020. Korean Gastric Cancer Association

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0/>) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ORCID iDs

Tetsuro Toriumi

<https://orcid.org/0000-0002-7205-0539>

Masanori Terashima

<https://orcid.org/0000-0002-2967-8267>

Funding

This study was supported in part by the National Cancer Center Research and Development Fund (29-A-3).

Author Contributions

Conceptualization: T.T.; Funding acquisition: T.M.; Investigation: T.T.; Supervision: T.M.; Writing - original draft: T.T.; Writing - review & editing: T.M.

Conflict of Interest

No potential conflict of interest relevant to this article was reported.

ABSTRACT

Splenic hilar lymph node dissection has been the standard treatment for advanced proximal gastric cancer. Splenectomy is typically performed as part of this procedure. However, splenectomy has some disadvantages, such as increased risk of postoperative complications, especially pancreatic fistula. Moreover, patients who underwent splenectomy are vulnerable to potentially fatal infection caused by encapsulated bacteria. Furthermore, several studies have shown an association of splenectomy with cancer development and increased risk of thromboembolic events. Therefore, splenectomy should be avoided if it does not confer a distinct oncological advantage. Most studies that compared patients who underwent splenectomy and those who did not failed to demonstrate the efficacy of splenectomy. Based on the results of a randomized controlled trial conducted in Japan, prophylactic dissection with splenectomy is no longer recommended in patients with gastric cancer with no invasion of the greater curvature. However, patients with greater curvature invasion or those with remnant gastric cancer still need to undergo splenectomy to facilitate splenic hilar node dissection. Spleen-preserving splenic hilar node dissection is a new procedure that may help delink splenic hilar node dissection and splenectomy. In this review, we examine the evidence pertaining to the efficacy and disadvantages of splenectomy. We discuss the possibility of spleen-preserving surgery for prophylactic splenic hilar node dissection to overcome the disadvantages of splenectomy.

Keywords: Gastric cancer; Lymph node dissection; Splenectomy; Review

INTRODUCTION

Despite the rapid advances in chemotherapy and molecular targeted therapy and development of immune checkpoint inhibitors, surgical resection with lymphadenectomy is the only curative treatment for gastric cancer. Approximately 10% of patients with advanced proximal gastric cancer develop splenic hilar lymph node (No. 10 lymph node) metastasis [1-13]. In Japan, No. 10 lymph node dissection with splenectomy has routinely been performed in these patients. In complete No. 10 lymph node dissection, splenectomy is considered to be essential. If the tumor directly invades the spleen or there is an obvious No. 10 lymph node metastasis, splenectomy should be performed for curative resection. However, there is no

clear consensus as to whether splenectomy should be performed in all patients undergoing prophylactic lymph node dissection. Since splenectomy is known to have some disadvantages [14,15], there is a need to demonstrate the survival benefit accruing from splenectomy in these patients. However, studies that have shown the efficacy of splenectomy in this respect are limited. One pivotal randomized controlled trial (RCT) from Japan [16] changed the gastric cancer treatment. Currently, prophylactic splenectomy is performed only in patients with advanced proximal gastric cancer with greater curvature invasion or in those with type 4 gastric cancer. There is still no clear evidence on the need for splenectomy in these patients. Recent studies have described spleen-preserving No. 10 lymph node dissection as a means to surmount the disadvantages of splenectomy while leveraging the benefits of No. 10 lymph node dissection [17-19]. The role of No. 10 lymph node dissection may be separately discussed from that of splenectomy. This procedure should be selected instead of splenectomy for prophylactic No. 10 lymph node dissection if backed by evidence.

In this review, we argue that prophylactic No. 10 lymph node dissection with splenectomy should not be performed in all cases. We investigate the evidence pertaining to the efficacy of splenectomy and discuss the disadvantages of No. 10 lymph node dissection with splenectomy. Moreover, we discuss the category of patients who may benefit from No. 10 lymph node dissection and consider spleen-preserving No. 10 lymph node dissection without splenectomy.

ANATOMY AND DISSECTION OF THE SPLENIC HILAR LYMPH NODE

According to the Japanese Classification of Gastric Carcinoma, the splenic hilar lymph node is defined as follows: "Splenic hilar lymph nodes including those adjacent to the splenic artery distal to the pancreatic tail, and those on the roots of the short gastric arteries and those along the left gastroepiploic artery proximal to its first gastric branch" [20]. Splenic hilar lymph node metastasis is common (approximate incidence, 10%) [1-13]. Moreover, prophylactic No. 10 lymph node dissection is considered to be effective in advanced gastric cancer. From the anatomical perspective, there is a complex network of peripheral branches of the splenic artery and vein in the splenic hilum. Moreover, there is considerable interindividual variability with respect to the vascular anatomy in the splenic hilum. For this reason, it is quite difficult to dissect all lymph nodes located around the splenic artery and vein, especially the posterior lymph nodes, without performing splenectomy. Therefore, splenectomy is considered as the standard technique for complete splenic hilar lymph node dissection.

EFFICACY OF SPLENECTOMY

We identified 4 prospective RCTs and 12 retrospective studies that compared splenectomy and spleen-preserving procedure without intentional No. 10 lymph node dissection for gastric cancer to assess the efficacy of splenic hilar dissection and splenectomy (**Table 1**). In the RCT (n=79) conducted by Toge et al. [21], splenectomy was shown to be associated with improved overall survival (OS). However, the sample size in this study was relatively small. The 3-year OS in the splenectomy group (n=41) and spleen-preserving surgery group (n=38) was 71.7% and 56.0% respectively, and this difference was statistically significant. However, there was no significant between-group difference in the 5-year OS. In the RCT by Csendes et al. [22], there were 90 patients in the splenectomy group and 97 patients in the spleen-preserving surgery

Table 1. Studies comparing splenectomy and spleen-preserving surgery without intentional No. 10 lymph node dissection

Study	Number	5-year OS (%)	Statistical significance	Effect of splenectomy
RCT				
Toge et al. [21]	SR=41 SP=38	3-year OS, 71.7 3-year OS, 56	0.02	Positive
Csendes et al. [22]	SR=90 SP=97	42 36	NS*	Equal
Galizia et al. [23]	SR(D2)=37 SP(D1+)=36	DFS 42.1 DFS 42.9	NS	Equal
Sano et al. [16]	SR=254 SP=251	75.1 76.4	Non-inferiority P=0.025	Equal
Retrospective study				
Sasada et al. [1]	SR=201 SP=148	NR	NR*	Equal
Verlato et al. [26]	SR=98 PR=43 SP=891	36.1 16.7 55.5	<0.001	Equal
Shen et al. [27]	SR=347 SP=102	NR NR	NS	Equal
Lee et al. [28]	SR=492 SP=173	52.9 64.8	<0.001*	Equal
Kasakura et al. [29]	SR=78 PR=105 SP=1,755	NR	NS	Equal
Erturk et al. [30]	SR=38 SP=23	44.7 47.8	NS	Equal
Otsuji et al. [31]	SR=57 PR=46 SP=25	55.9 45.7 54.2	NS	Equal
Zhang et al. [24]	SR=100 SP=114	28.8 33.8	0.013	Negative
Wang et al. [32]	SR=172 SP=291	47 51	NS†	Equal
Otsuji et al. [33]	SR=154 SP=91	46 47	NS	Equal
Nashimoto et al. [25]	SR=241 SP=264	NR NR	NR‡	Negative
Ito et al. [2]	SR=41 SP=88	NR NR	0.005	Negative

RCT, randomized controlled trial; SR, spleen resection; SP, spleen preservation; PR, pancreatic resection; OS, overall survival; DFS, disease-free survival; NR, not reported; NS, not significant.

*NS after stratification by stage; †NS after stratification by T and N stages; ‡Significantly negative in patients with pSE, pN2, and pStage IIIB.

group. Clinicopathological characteristics were comparable between the 2 groups. The 5-year OS was not significantly different between the 2 groups (42% and 36%, respectively). They also performed a subgroup analysis of 5-year OS disaggregated by disease stage. Although there were no significant between-group differences across all stages, patients with advanced-stage disease showed slightly better survival after splenectomy. These studies included gastric cancer in all circumferential locations, and the differences in tumor location were not considered. This may have influenced the results. In the study by Galizia et al. [23], splenectomy did not improve the disease-free survival (DFS). This study differed from other studies in that it included only lymph node positive patients (any regional lymph nodes) after randomization. The clinicopathologic characteristics were comparable between the splenectomy group (n=37) and spleen-preserving surgery group (n=36), except for the number of retrieved lymph nodes. The 5-year DFS was comparable in the splenectomy and spleen-preserving surgery groups (42.1% and 42.9%, respectively). However, this was not an RCT in the true sense, owing to the small sample size and inclusion of only lymph node positive patients. Lastly, Sano et al.

[16] conducted a phase III RCT that showed non-inferiority of spleen-preserving surgery. They included patients with advanced proximal gastric cancer without invasion of the greater curvature line. The 5-year OS in the splenectomy (n=254) and spleen-preserving surgery groups (n=251) was 75.1% and 76%, respectively. The study demonstrated statistically significant non-inferiority of spleen-preserving surgery. The findings suggested that splenectomy need not be performed in patients who meet the inclusion criteria. In this study, splenic hilar metastatic rate was 2.4% in the splenectomy group. This is a relatively low rate compared to those in other studies and probably attributable to the lack of inclusion of patients with greater curvature invasion. This implies that splenic hilar lymph node metastasis is more common in cancer with greater curvature invasion, which seems plausible. This was a well-designed pivotal study with a relatively large sample size. After this trial, the Japanese Gastric Cancer Treatment Guidelines were modified with respect to the indications for splenectomy. The revised guidelines no longer recommended splenectomy if the tumor has not invaded the greater curvature. Among these RCTs, splenectomy showed only marginally positive results in 1 trial with a small sample size. All other trials failed to demonstrate the superiority of splenectomy over spleen-preserving surgery. This inconsistency may be attributable to the inclusion criteria. Inclusion of patients with gastric cancer with greater curvature invasion may affect the results.

None of the retrospective studies have demonstrated any survival benefit conferred by splenectomy. Since patients are not randomly assigned in retrospective studies, the clinicopathologic characteristics were not comparable between the splenectomy and spleen-preserving surgery groups in most studies. The splenectomy group typically included patients with more advanced gastric cancer (e.g., tumor depth, lymph node metastasis, tumor size, undifferentiated type) with relatively poor prognosis. This difference should be considered when interpreting the results. Some studies accounted for differences in background characteristics by comparing patients in the same stage. Three such studies found a negative effect of splenectomy on survival [2,24,25]. The other 9 studies [1,26-33] concluded that splenectomy has neither positive nor negative impact on survival. The slightly negative results of splenectomy may be attributable to the difference in background characteristics. In most of the cases, splenectomy was performed in patients with more advanced gastric cancer.

The results of RCTs and retrospective studies seem to suggest that splenectomy does not have any impact on survival in patients without greater curvature invasion. Splenectomy may potentially be more effective in cancer with greater curvature invasion. However, there is no robust evidence to support this hypothesis.

DISADVANTAGES RELATED TO SPLENIC HILAR LYMPH NODE DISSECTION WITH SPLENECTOMY

The efficacy of No. 10 lymph node dissection with splenectomy has not been proven. However, some disadvantages related to splenectomy have been reported [14]. It increases the incidence of postoperative complications, especially pancreatic fistula, infection caused by encapsulated bacteria, cancer, and postoperative thrombosis. Owing to these disadvantages, unnecessary splenectomy should be avoided.

Postoperative complications

Table 2 presents a list of the studies that have reported the association of splenectomy with morbidity and mortality. Three RCTs that compared the abovementioned prognostic

Table 2. Comparison of complications between splenectomy and spleen-preserving surgery without intentional No. 10 lymph node dissection

Study	Number	Overall complication (%)	P	Leakage (%)	P	Pancreatic fistula (%)	P	Peritoneal abscess (%)	P	Mortality (%)	P
RCT											
Csendes et al. [22]	SR=90	NR	NR	NR	NS	NR	NR	11.0	<0.05	4.4	NS
	SP=97	NR		NR		NR		4.0		3.1	
Galizia et al. [23]	SR=37	48.6	NR	5.4	NR	16.2	NR	10.8	NR	5.4	NR
	SP=36	19.4		5.5		0		2.7		0	
Sano et al. [16]	SR=254	30.3	<0.01	4.3	NS	12.6	<0.0001	7.9	NS	0.4	NR
	SP=251	16.7		3.2		2.4		4.0		0.8	
Bonenkamp et al. [35]	SR=124	44.4	NR	NR	NR	NR	NR	NR	NR	15 (12.1%)	NR
	SP=204	17.6								6 (2.9%)	
Cuschieri et al. [34]	SR=131	59	<0.001	NR	NR	NR	NR	NR	NR	17	<0.001
	SP=69	22								4	
	PR=113	58	<0.001							16	0.01
	PP=87	30								9	
Kodera et al. [36]	SR=191	33.5	NS*	NR	NR	NR	NR	NR	NR	NR	NR
	SP=332	19.3									
	PR=22	59.1	0.001*								
	PP=501	23.0									
Retrospective study											
Sasada et al. [1]	SR=201	27.6	NR	6	NS	8.5	<0.001	5.0	NS	0.5	NR
	SP=148	21.6		3.4		0		2.0		0	
Verlato et al. [26]	SR=98	29.6	<0.001	NR	NR	NR	NR	NR	NR	5.0 [‡]	NS
	PR=43	39.5									
Lee et al. [28]	SP=891	17.4								3.7	
	SR=492	NR	NR	NR	NR	NR	NR	NR	NR	0.6	NR
Kasakura et al. [29]	SP=173	NR								0	
	SR=78	39.7	0.0001	9	<0.0001	5.1	<0.0001	3.8	<0.0001	0	0.0204
Erturk et al. [30]	PR=105	75.2		15.2		31.4		18.1		0.95	
	SP=1,755	17.8		5		0.5		1.0		0.06	
Otsuji et al. [31]	SR=38	9.83	NS	5.26	NS	2.63	NS	NR	NR	NR	NR
	SP=23	3.27		4.34		0					
Zhang et al. [24]	SR=57	40.4	NR	14.1	NS	1.8	0.027 [†]	NR	NR	NR	NR
	PR=46	45.7		15.2		15.2					
	SP=25	36.0		12		4.0					
Wang et al. [32]	SR=100	24	0.005	7	NR	NR	NR	7.0	NR	NR	NR
	SP=114	10		0				1.8			
Otsuji et al. [33]	SR=172	NR	NS	11.6	NS	NR	NR	4.7	NS	4.1	NS
	SP=291	NR		7.2				5.2		4.8	
Nashimoto et al. [25]	SR=154	NR	0.0077	15.8	<0.05	9.1	NS	NR	NR	NR	NR
	SP=91	NR		6.6		4.4					
Ohkura et al. [38]	SR=241	NR	NS	1.6	NS	12.9	0.008	NR	NR	NR	NR
	SP=264	NR		0.4		6.0					
Ohkura et al. [38]	SR=63	30.2	0.041	3.2	NS	1.7	0.003	NR	NR	NR	NR
	SP=45	13.3		6.7		0					

RCT, randomized controlled trial; SR, spleen resection; SP, spleen preservation; PR, pancreatic resection; PP, pancreatic preservation; NR, not reported; NS, not significant.

*P<0.001 on univariate analysis; [†]SP vs. SR and PR; [‡]SP and PR.

outcomes also compared the mortality and morbidity rate between the groups. Csendes et al. [22] reported no significant difference in mortality between the splenectomy and spleen-preserving surgery groups (4.4% and 3.1%, respectively). The incidence of abdominal abscess was significantly higher in the splenectomy group (11% vs. 4%, respectively; P<0.05). Anastomotic leakage rate was similar in both groups, while none of the patients in either group developed any pancreatic complication. The overall complication rate was not reported by the authors. Galizia et al. [23] reported the details of complication. The overall complication rates in the splenectomy and spleen-preserving surgery groups were

48.6% and 19.4%. The respective incidence rates of other complications were as follows: anastomotic leakage, 5.4% and 5.5%; pancreatic fistula, 16.2% and 0%; and intraabdominal abscess, 10.8% and 2.7%. The mortality rates in the 2 groups were 5.4% and 0%, respectively. Although the authors did not report the statistical results, it seems that complications (except anastomotic leakage) were more common in the splenectomy group. Mortality event occurred only in the splenectomy group; however, the number of patients included in this study was small, and mortality event occurred only in 2 patients. Sano et al. [16] also reported a higher incidence of complications in the splenectomy group. The overall incidence of complications was 30.3% in the splenectomy group and 16.7% in the spleen-preserving surgery group ($P < 0.01$). Anastomotic leakage rates were similar (4.3% and 3.2%, $P = 0.47$), while pancreatic fistula was more frequent in the splenectomy group (12.6% and 2.4%, $P < 0.0001$). Intraabdominal abscess was slightly more frequent in the splenectomy group (7.9% and 4%); however, the between-group difference was not statistically significant ($P = 0.089$). Mortality rate was not significantly different between the 2 groups (0.4% and 0.8%, respectively). All these RCTs showed consistent results; that is, splenectomy increased the incidence of pancreatic fistula and intraabdominal abscess, but not that of anastomotic leakage or mortality.

Some RCTs investigated the adequate extent of lymph node dissection and assessed the relationship between complications and splenectomy. Cuschieri et al. [34] and Bonenkamp et al. [35] compared D1 and D2 lymphadenectomy in the Western population. The former included 131 patients who underwent splenectomy and 69 patients who underwent spleen-preserving surgery in the D2 group. The complication rates were 59% and 22%, respectively ($P < 0.001$), and the mortality rates were 17% and 4%, respectively ($P < 0.001$). The splenectomy group showed worse morbidity and mortality. Similarly, in the study by Bonenkamp et al. [35], the overall morbidity and mortality rates were 44.4% and 12.1%, respectively, in the splenectomy group and 17.6% and 2.9%, respectively, in the spleen-preserving surgery group. These trials demonstrated an unfavorable effect of splenectomy on morbidity and mortality. However, it is noteworthy that the morbidity and mortality rates in these studies were extremely high. These trials were conducted in Western countries that have a relatively low incidence of gastric cancer; moreover, the studies were conducted >20 years ago. Low hospital volume and shortage of experience on D2 lymphadenectomy may have affected the outcomes. In contrast, Kodera et al. [36] presented a detailed analysis of JCOG9501 [37], which compared D2 and D2 + paraaortic lymph node dissection, to clarify the risk factors for complications. They found that splenectomy did not have an effect on the morbidity rate. The overall complication rates in the splenectomy and spleen-preserving surgery groups were 33.5% and 19.3%, respectively. In the univariate analysis, the between-group difference was statistically significant ($P < 0.001$); however, this was not the case in the multivariate analysis ($P = 0.304$). The overall complication rates were relatively high in this study. However, the criteria for complications were not well defined in this study; therefore, comparison of results with other studies is not straightforward. This trial included patients who underwent paraaortic lymph node dissection. This procedure tends to increase the morbidity and may have affected the results of the multivariate analysis.

Most retrospective studies also showed the negative impact of splenectomy on morbidity. Eleven studies reported the association of splenectomy with morbidity or mortality [1,24-26,28-33,38]. Five studies showed a significant negative effect of splenectomy on overall morbidity, while 3 studies showed no significant between-group difference. Anastomotic leakage was more frequent only in 2 studies, while 6 studies found no significant between-group difference. Intraabdominal

abscess was reported in only 4 studies, and 2 of these found no significant between-group difference. In contrast, the incidence of pancreatic fistula seemed to be affected by splenectomy; 5 studies found unfavorable effect of splenectomy, while 2 studies found no significant between-group difference. Both RCTs and retrospective studies showed a similar trend; namely, splenectomy increases the incidence of pancreatic fistula and overall complication rate, although it does not affect the incidence of anastomotic leakage. Splenectomy entails manipulation of the pancreas and mobilization of the pancreatic tail, which increases the risk of pancreatic injury. Moreover, ligation of the splenic artery proximal to the great pancreatic artery renders the pancreatic tail vulnerable to ischemia, leading to pancreatic fistula. Mortality rate was similar in all these studies. Advances in the treatment of major surgical complications have helped decrease the mortality rate.

Overwhelming post-splenectomy infection (OPSI)

The spleen has a crucial role in immunity by removing bacteria and antigen-antibody complexes from the bloodstream. The spleen also stimulates the production of immunoglobulin (Ig) M protein and antibodies against pneumococcal capsular polysaccharide, which facilitate phagocytosis by opsonization. Encapsulated organisms (e.g., *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Neisseria meningitidis*) evade phagocytosis if they are not opsonized. Therefore, patients who underwent splenectomy are vulnerable to infection by encapsulated pathogens. Among these, *S. pneumoniae* is the most frequent cause of severe infection [39,40]. OPSI is a serious disease developing in patients who underwent splenectomy. It is a fulminant condition associated with an extremely high mortality rate (36%–69%) [41]; therefore, prophylaxis against OPSI is quite important for these patients. All patients who underwent splenectomy are recommended to receive pneumococcal vaccine, *H. influenzae* type b vaccine, and meningococcal vaccine [42]. However, vaccination does not eliminate the risk of OPSI as these vaccines do not target all subtypes. A patient who underwent splenectomy has to live with the risk of OPSI and need to undergo regular vaccination. Splenectomy should be avoided if it does not confer a distinct advantage during gastric cancer surgery.

Relationship to development of cancer

The important role of immune function in cancer development has been increasingly recognized recently. Immune checkpoint inhibitors are currently used in patients with gastric cancer. The spleen is one of the most important organs for immunological function, and its role in cancer development or cancer suppression has been investigated recently. The effect of splenectomy on cancer is unclear. A large observational study investigated the relationship between splenectomy and cancer development [14]. If splenectomy increases the risk of cancer development, prophylactic splenectomy should be avoided. We reviewed the studies that investigated this subject. Three studies compared the risk of cancer development between patients who underwent splenectomy and those with functioning spleen [43-45]. Patients who underwent splenectomy were divided into 2 groups; splenectomy performed due to trauma and splenectomy performed for other reasons. Mellemkjoer et al. [43] found that the risk of cancer development did not increase in 1,103 patients who underwent splenectomy due to trauma (relative risk [RR], 1.0; 95% confidence interval [CI], 0.6–1.6). In contrast, patients who underwent splenectomy due to other conditions showed a higher risk of malignant neoplasms (RR, 2.2; 95% CI, 1.6–2.9). The most common neoplasms were lung cancer, non-melanoma skin cancer, and leukemia. Sun et al. [44] reported similar results. The hazard ratio (HR) for overall cancer was 1.29 (95% CI, 1.05–1.6) in patients with trauma and 2.64 (95% CI, 2.30–3.05) in patients without trauma compared with patients who did not undergo splenectomy. The incidence rates of esophageal, gastric, and liver cancers and

non-Hodgkin's lymphoma were increased in both groups. In a study by Linet et al. [45], the standardized incidence rates were 1.1 (95% CI, 0.8–1.5) in patients with trauma and 1.4 (95% CI, 1.1–1.6) in patients without trauma. All these studies showed that patients who underwent splenectomy tend to have a risk of cancer development; the risk is especially noticeable in patients who underwent splenectomy due to conditions other than trauma. Some studies have investigated the relationship between the immune system and splenectomy associated with gastric cancer. Saji et al. [46] reported 2 distinct patterns of the effect of splenectomy on post-gastrectomy survival, based on the levels of immunosuppressive acid protein (IAP). This study included 253 patients with gastric cancer. Patients who underwent splenectomy with low preoperative serum IAP level (<580 µg/mL) (which reflects positive antitumor immune reactions) showed a higher mortality rate (risk ratio=1.35 versus patients without splenectomy). Splenectomy had a negative effect in these patients. However, in the high IAP group (≥580 µg/mL), mortality rate was similar between the splenectomy and spleen-preserving surgery groups (risk ratio=2.26 and 2.24, respectively). Thus, splenectomy had a positive effect in patients with high IAP levels. Immunotherapy was also affected by the IAP levels and splenectomy. In case of low IAP levels, immunotherapy showed favorable effect, and the effect was greater in the spleen-preserving surgery group. However, in the high IAP group, immunotherapy had some negative effects in patients with preserved spleen and better results in patients who underwent splenectomy. They concluded that the spleen exhibits biphasic activity in terms of antitumor immune response depending on the IAP level. Some studies focused on circulating T-lymphocyte subsets after splenectomy in patients with gastric cancer [47,48]. Cho et al. [47] investigated the proportion of lymphocytes in 40 patients with stage III gastric cancer who underwent curative total gastrectomy with or without splenectomy. They compared the CD3, CD4, CD8, CD16, CD19, and CD25 levels between the 2 groups. The 5-year DFS rate was comparable in the splenectomy and spleen-preserving surgery groups (52.4% and 50.0%, respectively). CD3, CD8, and CD25 levels were significantly higher in the splenectomy group only at 3 postoperative months. CD16 level was significantly higher in the splenectomy group after 3 postoperative months. CD4 level was significantly lower in the splenectomy group only at 3 postoperative months. CD19 showed no difference at any time during the observation period. Only CD16 level was significantly different in the long term. These findings suggest that patients who underwent splenectomy have more natural killer cells, while there was no survival or oncological benefit from splenectomy. The authors concluded that splenectomy did not affect postoperative survival. Pan et al. [48] compared the CD3, CD4, CD8, IgG, IgA, and IgM levels in the splenectomy and spleen-preserving surgery groups consisting of patients with stage IV gastric cancer who underwent palliative surgery. After 6 postoperative months, all these immune indices, except CD8, were significantly lower in the splenectomy group. However, there was no significant between-group difference in survival, and the role of these immune indices is uncertain.

These reports suggest that splenectomy influences the immune system. While it is not related with cancer recurrence, it may affect other cancer developments in the long term. Splenectomy may also potentially affect the efficacy of immunotherapy. The details of the changes in the immune system after splenectomy or the effect of splenectomy on some treatments are still unclear. Further studies in this field may help assess the importance of splenectomy.

Post-splenectomy thrombosis

Thrombosis is a critical and potentially fatal complication. Few studies have investigated the relationship between thrombosis and splenectomy performed concomitantly with gastrectomy for gastric cancer; however, splenectomy has been shown to increase the risk

of thrombosis. Virchow's triad (hypercoagulability, hemodynamic changes, and endothelial injury) refers to the 3 main factors that contribute to thrombosis. Malignancy is believed to contribute to hypercoagulability, and splenectomy itself may be an independent factor for hypercoagulable status. Pommerening et al. [49] used serial rapid thromboelastography and demonstrated that splenectomy is associated with hypercoagulable state at least 120 hours postoperatively. They also reported a higher rate of thromboembolic complications in patients who underwent splenectomy (17.5% vs. 7.8%; $P=0.015$). Although this study included only patients with trauma and the operative situation is different from that of elective surgery, this study showed the relationship between splenectomy and hypercoagulability. Mukherjee et al. [50] compared the risk of venous thromboembolism according to the type of surgery. They compared bariatric surgery, colorectal surgery, esophagectomy, gastrectomy, hepatectomy, nephrectomy, pancreatectomy, and splenectomy. This study had an extremely large sample size that involved 375,748 patients. The odds ratio (OR) for venous thromboembolism was the highest in patients who underwent splenectomy (OR, 2.69; 95% CI, 2.03–3.56) even after adjusting for age, sex, year, Charlson score, length of stay, hospital teaching status, elective procedure status, trauma, and malignancy. However, the authors did not control the prophylactic use of anticoagulants in their analysis. As a result, bariatric surgery, which increases the risk for thrombosis, showed the lowest risk of thromboembolism probably due to anticoagulant use. Whether splenectomy had the highest risk among the procedures is uncertain. However, this study showed that splenectomy is a risk factor for postoperative thrombosis.

Splenectomy may be related to not only deep venous thrombosis (DVT) and pulmonary embolism (PE) but also portomesenteric venous thrombosis (PMVT). In the study by Boyle et al., the incidence rates of both DVT/PE and PMVT were increased after splenectomy [51]. They retrospectively analyzed data of 9,976 patients with immune thrombocytopenia. They compared cumulative incidence of DVT/PE and PMVT between patients who underwent splenectomy and those who did not undergo splenectomy. The incidence rates of DVT/PE in patients who underwent splenectomy and those who did not undergo splenectomy were 4.3% and 1.7%, respectively ($P<0.0001$). The corresponding incidence rate of PMVT were 1.6% and 1%, respectively ($P=0.0544$). They also focused on the time elapsed between surgery and the development of thrombosis. They defined <90 days after surgery as early thrombosis and ≥ 90 days as late thrombosis. Regarding PMVT, splenectomy was associated with increased HR for early PMVT (HR, 5.4; 95% CI, 2.3–12.5) but not for late PMVT (HR, 1.5; 95% CI, 0.9–2.6). In contrast, splenectomy increased the incidence of both early and late DVT/PE (HR, 5.2; 95% CI, 3.2–8.5; HR, 2.7; 95% CI, 1.9–3.8). These findings suggest that we should prevent both PMVT and DVT/PE in the early phase after splenectomy and DVT/PE even in the late phase. In a study by Han et al. [52], 31 of 4611 patients (0.67%) who underwent gastric surgery developed PMVT. In the multivariate analysis, advanced gastric cancer stage (RR, 2.236; 95% CI, 1.017–4.919), synchronous malignancies (RR, 29.236; 95% CI, 10.451–81.785), and splenectomy (RR, 8.563; 95% CI, 3.233–22.648) were independent risk factors for PMVT. In addition to the systemic factors (hypercoagulability), the procedure for splenectomy per se has some locoregional effects (hemodynamic changes and endothelial injury). Splenectomy entails manipulation of the splenic or portal vein and mobilization of the distal pancreas. The former procedure may cause endothelial injury during clamping of the vessels by tweezers, and the latter procedure tends to induce hemodynamic changes. Postoperative pancreatic fistula may also be related with PMVT due to the inflammation around the splenic vein, leading to a hypercoagulable state. As a result, PMVT tends to develop in the early phase [51,53].

Extremely few studies have assessed the relationship between splenectomy performed in conjunction with gastric cancer surgery and thrombosis. Theoretically, splenectomy increases the risk of thrombosis; however, the increased risk of thrombosis has been reported only in patients who underwent splenectomy for reasons other than gastric cancer surgery. Thrombosis is a rare but potentially fatal complication. We should be conscious of this complication in the long period after splenectomy.

IS SPLENECTOMY NOT NEEDED ANYMORE?

Several disadvantages of splenectomy have been reported. However, there are some situations wherein it would be better to perform splenectomy during gastric cancer surgery.

Risk factors for No. 10 lymph node metastasis

The therapeutic effect of splenectomy has not been adequately evaluated. In most studies that compared splenectomy and spleen-preserving surgery, patients with direct invasion of the spleen or those with obvious No. 10 lymph node metastasis were excluded. Huang et al. [54] retrospectively compared patients with No. 10 lymph node metastasis who underwent splenectomy (n=73) or spleen-preserving surgery with No. 10 lymph node dissection (n=143). The 5-year OS in the 2 groups were 30% and 19.7%, respectively (P<0.0001). This study suggested that splenectomy may be effective as a therapeutic intervention. It is also important to be conscious of the pattern of No. 10 lymph node metastasis. **Table 3** shows the studies that reported clinicopathological characteristics and risk factors for No. 10 lymph node metastasis. In several studies, type 4 tumor, tumor invading the greater curvature, deep invasion into the gastric wall, and presence of lymph node metastasis were related to No. 10 lymph node metastasis. More advanced cancer is typically associated with more extensive lymph node metastasis. The No. 10 lymph node is located near the greater curvature. From the perspective of lymphatic drainage, No. 10 lymph node metastasis will occur through No. 4sa or 4sb lymph nodes located along the greater curvature. On the contrary, in case of tumors located in the lesser curvature, the cancer cells will have to pass through many lymph nodes, like No. 1 and 3 lymph nodes to No. 7, 9, and 11 lymph nodes to reach the No. 10 lymph node. It is important to verify the necessity of splenectomy in patients with advanced proximal gastric cancer with invasion of the greater curvature.

Table 3. Risk factors for No. 10 lymph node metastasis

Study	Number	No. 10 lymph node metastasis (%)	Risk factors for No. 10 lymph node metastasis
Sasada et al. [1]	201	15.4	Gre, Post, or Circ; T4; younger
Ito et al. [2]	129	10.9	≥pT3, multiple lymph node metastasis, ≥3 cm
Kunisaki et al. [3]	118	7.3	Gre, No. 16 metastasis, advanced stage, larger, Siewert type III
Zhu et al. [4]	265	27.9	Advanced pT, advanced pN, distant lymph node metastasis
Ishikawa et al. [5]	127	9.4	≥T2
Huang et al. [6]	346	10.1	Not Less, pT4, No. 7 metastasis, No. 11 metastasis
Shin et al. [7]	319	12.9	Type 4, advanced T, advanced N, advanced stage, ≥5 cm, undifferentiated, female
Jeong et al. [8]	665	9.5	Gre or Circ, ≥stage III, larger, undifferentiated, LVI(+)
Kosuga et al. [9]	280	10.7	Gre, type 4
Chen et al. [10]	205	8.8	Gre or Post, pN stage, T4b, N3, No. 4sa metastasis, M1, stage IIIC–IV, ≥5 cm
Hong et al. [11]	398	9.6	cT4, cN positive, ≥5 cm
Li et al. [12]	108	2.8	Gre, ≥T3
Aoyagi et al. [13]	191	10.5	Gre or Circ; No. 4sa, 4sb, or 11 metastasis; advanced stage

Gre, greater curvature; Post, posterior; Circ, circumferential; Less, lesser curvature; LVI, lymphovascular invasion.

Table 4. Studies discussing the efficacy of splenectomy in patients with gastric cancer with greater curvature invasion

Study	No. 10 lymph node metastasis (%)	Number	5-year OS	TVI
Maezawa et al. [55]	13.4	Gre=82	30.0*	4.02
Watanabe et al. [56]	15.9	Gre=132	41.9	5.6
	6.2	Non-Gre=289	64.5	2
Jeong et al. [8]	24.1	Gre=145	18*	4.4
	5.4	Non-Gre=520	36*	2
Yura et al. [57]	15.1	Gre=212	46.9*	7.1
	4.2	Non-Gre=381	55.6*	2.3
Kosuga et al. [9]	10.7	Overall=280	43.0	5.49
	19.4	Gre=31	100.0*	19.4
	7.2	Non-Gre=181	64.6*	4.64
	16.2	Circ=68	10.0*	1.62

OS, overall survival; TVI, therapeutic value index.

*OS in patients with No. 10 lymph node metastasis.

Table 4 shows the studies that investigated this issue. Five studies [8,9,55-57] used therapeutic value index (TVI) to evaluate the efficacy of splenectomy in patients with advanced gastric cancer with greater curvature invasion. TVI is calculated by multiplying the incidence of No. 10 lymph node metastasis by the 5-year survival rate of patients with No. 10 lymph node metastasis. Four studies compared TVI between patients with invasion of the greater curvature (Gre group) and those with no invasion of the greater curvature (non-Gre group). In these studies, the incidence rate of No. 10 lymph node metastasis in the Gre group ranged from 13.4% to 24.1%, which was higher than the overall metastatic rate. TVI was also higher in the Gre group. All authors concluded that splenectomy may be effective in the Gre group. However, they did not directly compare patients with greater curvature invasion in the splenectomy and spleen-preserving surgery groups. Therefore, no definitive conclusions can be drawn from these studies.

One retrospective study [38] compared patients with advanced proximal gastric cancer with greater curvature invasion in the splenectomy and spleen-preserving surgery groups. The clinicopathological features were comparable between the 2 groups. The 5-year OS of patients in the splenectomy and spleen-preserving surgery groups was 63.7% and 73.6%, respectively. This study suggested that splenectomy is unnecessary even in patients in the Gre group. However, the metastatic rate was only 6% and lower than that in other studies. Besides, 76% of patients in the spleen-preserving surgery group underwent No. 10 lymph node dissection or pickup. These factors probably affected the outcome, and it does not imply that No. 10 lymph node dissection is unnecessary. Advanced gastric cancer with greater curvature invasion is a risk factor of No. 10 lymph node metastasis, and these patients may benefit from No. 10 lymph node dissection.

Patients with remnant gastric cancer

Since remnant gastric cancer is a relatively rare disease, the efficacy of splenectomy on remnant gastric cancer is inadequately discussed. The lymphatic pathways tend to change especially after surgery for malignant cancer. Dissection of lymph nodes along the lesser curvature during initial surgery will hinder the lymphatic drainage of the lesser curvature and lead to the development of an alternative lymphatic pathway to the splenic hilar nodes [58,59]. This change may increase the incidence of No. 10 lymph node metastasis, and splenectomy may have a beneficial effect in these patients. A few studies have investigated the efficacy of splenectomy in the context of remnant gastric cancer surgery. Sugita et al. [60] analyzed the effect of splenectomy. In the T1/2 group, there were no No. 10 lymph node metastasis and no

difference in 5-year OS. However, in the T3/4 population, the No. 10 lymph node metastatic rate was 30.4%, which was higher than that observed in the context of primary cancer. Moreover, the 5-year OS was significantly better in the splenectomy group ($P < 0.05$). Although the authors did not stratify the patients by disease stage, patients with advanced remnant gastric cancer may benefit from splenectomy. Ohashi et al. [61] also reported the potentially therapeutic benefit of dissection of splenic hilar nodes. They included patients with T2–4 remnant gastric cancer after surgery for malignancy; the TVI in these patients (3.38) was higher than that for other lymph node stations. In contrast, Son et al. [58] found that splenectomy did not have an effect on survival outcomes. In the subgroup analysis disaggregated by disease stage, they found no significant difference between the splenectomy and non-splenectomy groups. In this study, patients with both benign and malignant diseases at initial surgery were included. Furthermore, there was a relatively low number of patients with advanced remnant gastric cancer, who may have benefited from splenectomy.

Theoretically, it seems better to perform splenectomy in patients with remnant gastric cancer especially after surgery for malignancy with lesser curvature dissection. However, further study is warranted to obtain definitive evidence in this regard.

NO. 10 LYMPH NODE DISSECTION WITHOUT SPLENECTOMY

Splenectomy is the standard treatment for advanced gastric cancer invading the greater curvature. However, owing to the aforementioned disadvantages, the indication for splenectomy should be carefully considered. In a therapeutic situation, splenectomy may be effective [54], while prophylactic splenectomy in patients in the Gre group (high risk for metastasis) is still controversial. Several recent studies have investigated spleen-preserving No. 10 lymph node dissection [62-72]. However, whether this procedure allows for adequate dissection is also controversial. Spleen-preserving No. 10 lymph node dissection is desirable if it is as effective as splenectomy and overcomes the disadvantages of splenectomy. **Table 5** shows the studies that compared splenectomy and spleen-preserving No. 10 lymph node dissection. None of these studies showed a beneficial effect of splenectomy. Spleen-preserving No. 10 lymph node dissection did not seem to worsen the OS. There is one RCT among these studies. Yu et al. [70] randomly assigned 207 patients to the splenectomy and spleen-preserving No. 10 lymph node dissection groups. The 5-year OS was comparable in the 2 groups (54.8% and 48.8%, respectively; $P = 0.503$). In other retrospective studies, splenectomy showed either a negative impact or no impact on survival. However, the splenectomy group tended to include more advanced cancer, and this bias should be taken into consideration. Huang et al. [73] had a different perspective. They retrospectively compared patients who underwent and did not undergo No. 10 lymph node dissection in the spleen-preserving surgery group. The 3-year DFS was significantly better in the dissection group in patients with stage III gastric cancer. This result suggests that No. 10 lymph node dissection without splenectomy is effective.

Spleen-preserving No. 10 lymph node dissection necessarily involves manipulation of the distal pancreas, which increases the risk of postoperative morbidity. **Table 6** shows the postoperative complication rate in the splenectomy and spleen-preserving dissection groups. Nine studies reported the total complication rate, and approximately half of these studies showed a significant increase in the splenectomy group. This result is similar to the results shown in **Table 2**. The total complication rate in the spleen-preserving No. 10 lymph

No. 10 Lymph Node Dissection: Cons

Table 5. Efficacy of splenectomy in spleen-preserving No. 10 lymph node dissection

Study	No. 10 lymph node metastasis (%)	Number	5-year OS (%)	P	Effect of splenectomy	Number of retrieved No. 10 lymph node	P
Yu et al. [70]	10.6	SR=104	54.8	NS	Equal	NR	
	5.8	SP=103	48.8				
Ji et al. [62]	32.3	SR=31	23	0.018	Negative	2	0.047
	14.4	SP (ex situ)=118	50				
	8.8	SP (in situ)=68	46				
Jeong et al. [63]	19.7	SR=229	55	<0.001	Negative	NR	
	2.1	SP=845	81				
	Propensity score matching						
		SR=97	65				
		SP=97	79				
Li et al. [64]	NR	SR=62	55	NS	Equal	5.4	NS
	NR	SP=69	66				
Qin et al. [65]	20.8	SR=216	57.4	<0.01	Equal	NR	
	17.5	SP=63	57.5				
	19.1	PR=30	37				
Fatouros et al. [66]	6	SR=67	NR	0.004	Negative	NR	
	0	SP=59	NR				
Kwon [67]	NR	SR=260	NR	0.0265*	Equal	NR	
	NR	SP=232	NR				
Oh et al. [68]	15.1	SR=99	56.7 months	<0.001*	Equal	NR	
	6	SP=267	72 months				
Son et al. [69]	9.1	SR=44	65.9	NS	Equal	3.21	0.033
	8.8	SP=68	77.3				
Usui et al. [71]	0	SR=19	NR		NR	2.4	NS
	0	SP=59	NR				
Zhang et al. [72]	23.7	SR=38	16.9	0.008	Negative	NR	
	12.9	SP=70	38.7				

SR, spleen resection; SP, spleen preservation; PR, pancreatic resection; OS, overall survival; NR, not reported; NS, not significant.

*NS after stratification by stage.

Table 6. Complications of splenectomy and spleen-preserving No. 10 lymph node dissection

Study	Number	Overall complication (%)	P	Leakage (%)	P	Pancreatic fistula (%)	P	Peritoneal abscess (%)	P	Mortality (%)	P
Yu et al. [70]	SR=104	15.4	NS	NR	NR	NR	NR	3.8	NS	NR	NR
	SP=103	8.7									
Ji et al. [62]	SR=31	35.5	0.005	16.1	NS	6.5	0.019	22.6	0.029	3.2	NS
	SP (ex situ)=118	12.7									
	SP (in situ)=68	17.6									
Jeong et al. [63]	SR=229	29.3	<0.001	NR	NR	NR	NR	NR	NR	NR	NR
	SP=845	19.8									
Qin et al. [65]	SR=216	4.2	NR	NR	NR	NR	NR	NR	NR	0.9	NR
	SP=63	0									
	PR=30	40.0									
Fatouros et al. [66]	SR=67	19.4	NS	12	NS*	NR	NR	NR	NR	0	NS
	SP=59	18.6									
Kwon [67]	SR=260	21.5	0.013	0.8	NR	1.5	NR	NR	NR	2.7	0.048
	SP=232	12.9									
Oh et al. [68]	SR=99	29.3	<0.001	0	1	NR	NR	NR	NR	1	NS
	SP=267	11.6									
Son et al. [69]	SR=44	13.6	NS	2.3	NR	4.5	NR	NR	NR	0	NR
	SP=68	17.6									
Usui et al. [71]	SR=19	NR		0	NS	15.8	NS	NR	NR	NR	NR
	SP=59	NR									
Zhang et al. [72]	SR=38	18.4	NS	NR	NR	NR	2.6	NR	NR	0	NR
	SP=70	14.0									

SR, spleen resection; SP, spleen preservation; PR, pancreatic resection; NR, not reported; NS, not significant.

*Leakage and abscess.

node dissection ranged from 11.6% to 19.8%, and this rate was also similar to the results in the spleen-preserving surgery group shown in **Table 2**. Among the complications, the incidence of anastomotic leakage was not different in any of the studies, while the incidence of pancreatic fistula decreased with spleen preservation. This result suggests that No. 10 lymph node dissection did not increase the postoperative morbidity compared with spleen preservation without No. 10 lymph node dissection.

Spleen-preserving No. 10 lymph node dissection did not worsen the prognosis and may decrease the complication rate. From these results, spleen-preserving No. 10 lymph node dissection would be a good surgical option for prophylactic dissection in advanced gastric cancer with greater curvature invasion, as an alternative to splenectomy.

CONCLUSIONS

Splenectomy is performed in a therapeutic situation or prophylactic dissection in patients with high risk of splenic hilar metastasis. However, splenectomy has some disadvantages. It definitely increases the risk of pancreatic fistula, infection with encapsulated bacteria, and thromboembolic events. Besides, it also affects the immune system, which may have a negative effect on survival, e.g., increasing the risk of cancer development. Due diligence should be exercised to avoid splenectomy, whenever possible. Spleen-preserving No. 10 lymph node dissection might be an alternative treatment for high-risk patients. This treatment does not appear to worsen the prognosis but decreases the postoperative complication rate and prevents other problems associated with splenectomy. However, robust evidence on the efficacy of this procedure is lacking, and further trials comparing splenectomy and spleen-preserving No. 10 lymph node dissection in patients with greater curvature invasion are required.

REFERENCES

1. Sasada S, Ninomiya M, Nishizaki M, Harano M, Ojima Y, Matsukawa H, et al. Frequency of lymph node metastasis to the splenic hilus and effect of splenectomy in proximal gastric cancer. *Anticancer Res* 2009;29:3347-3351.
[PUBMED](#)
2. Ito H, Inoue H, Odaka N, Satodate H, Mukai S, Omoto T, et al. Prognostic impact of prophylactic splenectomy for upper-third gastric cancer: a cohort study. *Anticancer Res* 2013;33:277-282.
[PUBMED](#)
3. Kunisaki C, Makino H, Suwa H, Sato T, Oshima T, Nagano Y, et al. Impact of splenectomy in patients with gastric adenocarcinoma of the cardia. *J Gastrointest Surg* 2007;11:1039-1044.
[PUBMED](#) | [CROSSREF](#)
4. Zhu GL, Sun Z, Wang ZN, Xu YY, Huang BJ, Xu Y, et al. Splenic hilar lymph node metastasis independently predicts poor survival for patients with gastric cancers in the upper and/or the middle third of the stomach. *J Surg Oncol* 2012;105:786-792.
[PUBMED](#) | [CROSSREF](#)
5. Ishikawa S, Shimada S, Miyanari N, Hirota M, Takamori H, Baba H. Pattern of lymph node involvement in proximal gastric cancer. *World J Surg* 2009;33:1687-1692.
[PUBMED](#) | [CROSSREF](#)
6. Huang CM, Zhang JR, Zheng CH, Li P, Xie JW, Wang JB, et al. A 346 case analysis for laparoscopic spleen-preserving no.10 lymph node dissection for proximal gastric cancer: a single center study. *PLoS One* 2014;9:e108480.
[PUBMED](#) | [CROSSREF](#)

7. Shin SH, Jung H, Choi SH, An JY, Choi MG, Noh JH, et al. Clinical significance of splenic hilar lymph node metastasis in proximal gastric cancer. *Ann Surg Oncol* 2009;16:1304-1309.
[PUBMED](#) | [CROSSREF](#)
8. Jeong O, Jung MR, Ryu SY. Clinicopathological features and prognostic impact of splenic hilar lymph node metastasis in proximal gastric carcinoma. *Eur J Surg Oncol* 2019;45:432-438.
[PUBMED](#) | [CROSSREF](#)
9. Kosuga T, Ichikawa D, Okamoto K, Komatsu S, Shiozaki A, Fujiwara H, et al. Survival benefits from splenic hilar lymph node dissection by splenectomy in gastric cancer patients: relative comparison of the benefits in subgroups of patients. *Gastric Cancer* 2011;14:172-177.
[PUBMED](#) | [CROSSREF](#)
10. Chen XL, Yang K, Zhang WH, Chen XZ, Zhang B, Chen ZX, et al. Metastasis, risk factors and prognostic significance of splenic hilar lymph nodes in gastric adenocarcinoma. *PLoS One* 2014;9:e99650.
[PUBMED](#) | [CROSSREF](#)
11. Hong ZL, Chen QY, Zheng CH, Li P, Xie JW, Wang JB, et al. A preoperative scoring system to predict the risk of No.10 lymph node metastasis for advanced upper gastric cancer: a large case report based on a single-center study. *Oncotarget* 2017;8:80050-80060.
[PUBMED](#) | [CROSSREF](#)
12. Li P, Huang CM, Zheng CH, Xie JW, Wang JB, Lin JX, et al. Laparoscopic spleen-preserving splenic hilar lymphadenectomy in 108 consecutive patients with upper gastric cancer. *World J Gastroenterol* 2014;20:11376-11383.
[PUBMED](#) | [CROSSREF](#)
13. Aoyagi K, Kouhujii K, Miyagi M, Imaizumi T, Kizaki J, Shirouzu K. Prognosis of metastatic splenic hilum lymph node in patients with gastric cancer after total gastrectomy and splenectomy. *World J Hepatol* 2010;2:81-86.
[PUBMED](#) | [CROSSREF](#)
14. Kristinsson SY, Gridley G, Hoover RN, Check D, Landgren O. Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up. *Haematologica* 2014;99:392-398.
[PUBMED](#) | [CROSSREF](#)
15. Zakeri S, Gorji N, Akhtari M, Moeini R. Splenectomy may have more complications than currently proven. *Med Hypotheses* 2018;112:43-46.
[PUBMED](#) | [CROSSREF](#)
16. Sano T, Sasako M, Mizusawa J, Yamamoto S, Katai H, Yoshikawa T, et al. Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma. *Ann Surg* 2017;265:277-283.
[PUBMED](#) | [CROSSREF](#)
17. Uyama I, Sugioka A, Sakurai Y, Komori Y, Hanai T, Matsui H, et al. Hand-assisted laparoscopic function-preserving and radical gastrectomies for advanced-stage proximal gastric cancer. *J Am Coll Surg* 2004;199:508-515.
[PUBMED](#) | [CROSSREF](#)
18. Huang CM, Chen QY, Lin JX, Zheng CH, Li P, Xie JW. Huang's three-step maneuver for laparoscopic spleen-preserving No. 10 lymph node dissection for advanced proximal gastric cancer. *Chin J Cancer Res* 2014;26:208-210.
[PUBMED](#) | [CROSSREF](#)
19. Kinoshita T, Shibasaki H, Enomoto N, Sahara Y, Sunagawa H, Nishida T. Laparoscopic splenic hilar lymph node dissection for proximal gastric cancer using integrated three-dimensional anatomic simulation software. *Surg Endosc* 2016;30:2613-2619.
[PUBMED](#) | [CROSSREF](#)
20. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. *Gastric Cancer* 2011;14:101-112.
[PUBMED](#) | [CROSSREF](#)
21. Toge T, Kameda A, Kuroi K, Seto Y, Yamada H, Hattori T. The role of the spleen in immunosuppression and the effects of splenectomy on prognosis in gastric cancer patients. *Nippon Geka Gakkai Zasshi* 1985;86:1120-1123.
[PUBMED](#)
22. Csendes A, Burdiles P, Rojas J, Braghetto I, Diaz JC, Maluenda F. A prospective randomized study comparing D2 total gastrectomy versus D2 total gastrectomy plus splenectomy in 187 patients with gastric carcinoma. *Surgery* 2002;131:401-407.
[PUBMED](#) | [CROSSREF](#)
23. Galizia G, Lieto E, De Vita F, Castellano P, Ferraraccio F, Zamboli A, et al. Modified versus standard D2 lymphadenectomy in total gastrectomy for nonjunctional gastric carcinoma with lymph node metastasis. *Surgery* 2015;157:285-296.
[PUBMED](#) | [CROSSREF](#)

24. Zhang H, Pang D, Xu H, Ren Y, Liu C. Is concomitant splenectomy beneficial for the long-term survival of patients with gastric cancer undergoing curative gastrectomy? A single-institution study. *World J Surg Oncol* 2014;12:193.
[PUBMED](#) | [CROSSREF](#)
25. Nashimoto A, Yabusaki H, Matsuki A. The significance of splenectomy for advanced proximal gastric cancer. *Int J Surg Oncol* 2012;2012:301530.
[PUBMED](#) | [CROSSREF](#)
26. Verlato G, Roviello F, Marchet A, Giacopuzzi S, Marrelli D, Nitti D, et al. Indexes of surgical quality in gastric cancer surgery: experience of an Italian network. *Ann Surg Oncol* 2009;16:594-602.
[PUBMED](#) | [CROSSREF](#)
27. Shen JG, Cheong JH, Hyung WJ, Kim J, Choi SH, Noh SH. Adverse effect of splenectomy on recurrence in total gastrectomy cancer patients with perioperative transfusion. *Am J Surg* 2006;192:301-305.
[PUBMED](#) | [CROSSREF](#)
28. Lee KY, Noh SH, Hyung WJ, Lee JH, Lah KH, Choi SH, et al. Impact of splenectomy for lymph node dissection on long-term surgical outcome in gastric cancer. *Ann Surg Oncol* 2001;8:402-406.
[PUBMED](#) | [CROSSREF](#)
29. Kasakura Y, Fujii M, Mochizuki F, Kochi M, Kaiga T. Is there a benefit of pancreaticosplenectomy with gastrectomy for advanced gastric cancer? *Am J Surg* 2000;179:237-242.
[PUBMED](#) | [CROSSREF](#)
30. Erturk S, Ersan Y, Cicek Y, Dogusoy G, Senocak M. Effect of simultaneous splenectomy on the survival of patients undergoing curative gastrectomy for proximal gastric carcinoma. *Surg Today* 2003;33:254-258.
[PUBMED](#) | [CROSSREF](#)
31. Otsuji E, Yamaguchi T, Sawai K, Okamoto K, Takahashi T. Total gastrectomy with simultaneous pancreaticosplenectomy or splenectomy in patients with advanced gastric carcinoma. *Br J Cancer* 1999;79:1789-1793.
[PUBMED](#) | [CROSSREF](#)
32. Wang F, Chang YC, Chen TH, Hsu JT, Kuo CJ, Lin CJ, et al. Prognostic significance of splenectomy for patients with gastric adenocarcinoma undergoing total gastrectomy: a retrospective cohort study. *Int J Surg* 2014;12:557-565.
[PUBMED](#) | [CROSSREF](#)
33. Otsuji E, Yamaguchi T, Sawai K, Ohara M, Takahashi T. End results of simultaneous splenectomy in patients undergoing total gastrectomy for gastric carcinoma. *Surgery* 1996;120:40-44.
[PUBMED](#) | [CROSSREF](#)
34. Cuschieri A, Fayers P, Fielding J, Craven J, Bancewicz J, Joypaul V, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. *Lancet* 1996;347:995-999.
[PUBMED](#) | [CROSSREF](#)
35. Bonenkamp JJ, Songun I, Hermans J, Sasako M, Welvaart K, Plukker JT, et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. *Lancet* 1995;345:745-748.
[PUBMED](#) | [CROSSREF](#)
36. Kodera Y, Sasako M, Yamamoto S, Sano T, Nashimoto A, Kurita A. Identification of risk factors for the development of complications following extended and superextended lymphadenectomies for gastric cancer. *Br J Surg* 2005;92:1103-1109.
[PUBMED](#) | [CROSSREF](#)
37. Sano T, Sasako M, Yamamoto S, Nashimoto A, Kurita A, Hiratsuka M, et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy--Japan Clinical Oncology Group study 9501. *J Clin Oncol* 2004;22:2767-2773.
[PUBMED](#) | [CROSSREF](#)
38. Ohkura Y, Haruta S, Shindoh J, Tanaka T, Ueno M, Udagawa H. Efficacy of prophylactic splenectomy for proximal advanced gastric cancer invading greater curvature. *World J Surg Oncol* 2017;15:106.
[PUBMED](#) | [CROSSREF](#)
39. Holdsworth RJ, Irving AD, Cuschieri A. Postsplenectomy sepsis and its mortality rate: actual versus perceived risks. *Br J Surg* 1991;78:1031-1038.
[PUBMED](#) | [CROSSREF](#)
40. Theilacker C, Ludewig K, Serr A, Schimpf J, Held J, Bögelein M, et al. Overwhelming postsplenectomy infection: a prospective multicenter cohort study. *Clin Infect Dis* 2016;62:871-878.
[PUBMED](#) | [CROSSREF](#)
41. Davidson RN, Wall RA. Prevention and management of infections in patients without a spleen. *Clin Microbiol Infect* 2001;7:657-660.
[PUBMED](#) | [CROSSREF](#)

42. Davies JM, Lewis MP, Wimperis J, Rafi I, Ladhani S, Bolton-Maggs PH. Review of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen: prepared on behalf of the British Committee for Standards in Haematology by a working party of the Haemato-Oncology task force. *Br J Haematol* 2011;155:308-317.
[PUBMED](#) | [CROSSREF](#)
43. Mellemkjoer L, Olsen JH, Linet MS, Gridley G, McLaughlin JK. Cancer risk after splenectomy. *Cancer* 1995;75:577-583.
[PUBMED](#) | [CROSSREF](#)
44. Linet MS, Nyrén O, Gridley G, Mellemkjaer L, McLaughlin JK, Olsen JH, et al. Risk of cancer following splenectomy. *Int J Cancer* 1996;66:611-616.
[PUBMED](#) | [CROSSREF](#)
45. Sun LM, Chen HJ, Jeng LB, Li TC, Wu SC, Kao CH. Splenectomy and increased subsequent cancer risk: a nationwide population-based cohort study. *Am J Surg* 2015;210:243-251.
[PUBMED](#) | [CROSSREF](#)
46. Saji S, Sakamoto J, Teramukai S, Kunieda K, Sugiyama Y, Ohashi Y, et al. Impact of splenectomy and immunochemotherapy on survival following gastrectomy for carcinoma: covariate interaction with immunosuppressive acidic protein, a serum marker for the host immune system. *Surg Today* 1999;29:504-510.
[PUBMED](#) | [CROSSREF](#)
47. Cho MY, Kroh MD, Joh YG, Suh SO. Impact of splenectomy on circulating T-lymphocyte subsets in stage III gastric cancer. *ANZ J Surg* 2002;72:411-416.
[PUBMED](#) | [CROSSREF](#)
48. Pan D, Chen H, Li LQ, Li ZF. Effect of splenectomy combined with resection for gastric carcinoma on patient prognosis. *Med Sci Monit* 2016;22:4205-4209.
[PUBMED](#) | [CROSSREF](#)
49. Pommerening MJ, Rahbar E, Minei K, Holcomb JB, Wade CE, Schreiber MA, et al. Splenectomy is associated with hypercoagulable thrombelastography values and increased risk of thromboembolism. *Surgery* 2015;158:618-626.
[PUBMED](#) | [CROSSREF](#)
50. Mukherjee D, Lidor AO, Chu KM, Gearhart SL, Haut ER, Chang DC. Postoperative venous thromboembolism rates vary significantly after different types of major abdominal operations. *J Gastrointest Surg* 2008;12:2015-2022.
[PUBMED](#) | [CROSSREF](#)
51. Boyle S, White RH, Brunson A, Wun T. Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia. *Blood* 2013;121:4782-4790.
[PUBMED](#) | [CROSSREF](#)
52. Han JW, Kong SH, Shin CI, Min SK, Min SI, Kim TH, et al. Portomesenteric vein thrombosis after gastric surgery. *Gastric Cancer* 2016;19:1135-1143.
[PUBMED](#) | [CROSSREF](#)
53. Kang CM, Chung YE, Jung MJ, Hwang HK, Choi SH, Lee WJ. Splenic vein thrombosis and pancreatic fistula after minimally invasive distal pancreatectomy. *Br J Surg* 2014;101:114-119.
[PUBMED](#) | [CROSSREF](#)
54. Huang CM, Wang JB, Lu HS, Zheng CH, Li P, Xie JW, et al. Prognostic impact of splenectomy on advanced proximal gastric cancer with No. 10 lymph node metastasis. *Chin Med J (Engl)* 2009;122:2757-2762.
[PUBMED](#)
55. Maezawa Y, Aoyama T, Yamada T, Kano K, Hayashi T, Sato T, et al. Priority of lymph node dissection for proximal gastric cancer invading the greater curvature. *Gastric Cancer* 2018;21:569-572.
[PUBMED](#) | [CROSSREF](#)
56. Watanabe M, Kinoshita T, Enomoto N, Shibasaki H, Nishida T. Clinical significance of splenic hilar dissection with splenectomy in advanced proximal gastric cancer: an analysis at a single institution in Japan. *World J Surg* 2016;40:1165-1171.
[PUBMED](#) | [CROSSREF](#)
57. Yura M, Yoshikawa T, Otsuki S, Yamagata Y, Morita S, Katai H, et al. The therapeutic survival benefit of splenic hilar nodal dissection for advanced proximal gastric cancer invading the greater curvature. *Ann Surg Oncol* 2019;26:829-835.
[PUBMED](#) | [CROSSREF](#)
58. Son SY, Kong SH, Ahn HS, Park YS, Ahn SH, Suh YS, et al. The value of N staging with the positive lymph node ratio, and splenectomy, for remnant gastric cancer: a multicenter retrospective study. *J Surg Oncol* 2017;116:884-893.
[PUBMED](#) | [CROSSREF](#)

59. Honda S, Bando E, Makuuchi R, Tokunaga M, Tanizawa Y, Kawamura T, et al. Effects of initial disease status on lymph flow following gastrectomy in cases of carcinoma in the remnant stomach. *Gastric Cancer* 2017;20:457-464.
[PUBMED](#) | [CROSSREF](#)
60. Sugita H, Oda E, Hirota M, Ishikawa S, Tomiyasu S, Tanaka H, et al. Significance of lymphadenectomy with splenectomy in radical surgery for advanced (pT3/pT4) remnant gastric cancer. *Surgery* 2016;159:1082-1089.
[PUBMED](#) | [CROSSREF](#)
61. Ohashi M, Morita S, Fukagawa T, Kushima R, Katai H. Surgical treatment of non-early gastric remnant carcinoma developing after distal gastrectomy for gastric cancer. *J Surg Oncol* 2015;111:208-212.
[PUBMED](#) | [CROSSREF](#)
62. Ji X, Fu T, Bu ZD, Zhang J, Wu XJ, Zong XL, et al. Comparison of different methods of splenic hilar lymph node dissection for advanced upper- and/or middle-third gastric cancer. *BMC Cancer* 2016;16:765.
[PUBMED](#) | [CROSSREF](#)
63. Jeong O, Kim HG, Ryu SY, Park YK, Jung MR. Adverse prognostic impact of splenectomy on survival in gastric carcinoma patients: regression and propensity score matching analysis of 1074 patients. *PLoS One* 2018;13:e0203820.
[PUBMED](#) | [CROSSREF](#)
64. Li C, Kim S, Lai JF, Oh SJ, Hyung WJ, Choi WH, et al. Lymph node dissection around the splenic artery and hilum in advanced middle third gastric carcinoma. *Eur J Surg Oncol* 2009;35:709-714.
[PUBMED](#) | [CROSSREF](#)
65. Qin H, Lin C. Radical resection of gastric carcinoma with pancreas and spleen preservation and functional cleaning of lymph nodes. *Chin Med J (Engl)* 2002;115:736-739.
[PUBMED](#)
66. Fatouros M, Roukos DH, Lorenz M, Arampatzis I, Hottentrott C, Encke A, et al. Impact of spleen preservation in patients with gastric cancer. *Anticancer Res* 2005;25:3023-3030.
[PUBMED](#)
67. Kwon SJ. Prognostic impact of splenectomy on gastric cancer: results of the Korean Gastric Cancer Study Group. *World J Surg* 1997;21:837-844.
[PUBMED](#) | [CROSSREF](#)
68. Oh SJ, Hyung WJ, Li C, Song J, Kang W, Rha SY, et al. The effect of spleen-preserving lymphadenectomy on surgical outcomes of locally advanced proximal gastric cancer. *J Surg Oncol* 2009;99:275-280.
[PUBMED](#) | [CROSSREF](#)
69. Son SY, Shin DJ, Park YS, Oo AM, Jung DH, Lee CM, et al. Spleen-preserving lymphadenectomy versus splenectomy in laparoscopic total gastrectomy for advanced gastric cancer. *Surg Oncol* 2017;26:207-211.
[PUBMED](#) | [CROSSREF](#)
70. Yu W, Choi GS, Chung HY. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. *Br J Surg* 2006;93:559-563.
[PUBMED](#) | [CROSSREF](#)
71. Usui S, Tashiro M, Haruki S, Arita K, Ito K, Matsumoto A, et al. Spleen preservation versus splenectomy in laparoscopic total gastrectomy with D2 lymphadenectomy for gastric cancer: a comparison of short-term outcomes. *Asian J Endosc Surg* 2016;9:5-13.
[PUBMED](#) | [CROSSREF](#)
72. Zhang CH, Zhan WH, He YL, Chen CQ, Huang MJ, Cai SR. Spleen preservation in radical surgery for gastric cardia cancer. *Ann Surg Oncol* 2007;14:1312-1319.
[PUBMED](#) | [CROSSREF](#)
73. Huang CM, Chen T, Lin JX, Chen QY, Zheng CH, Li P, et al. The effects of laparoscopic spleen-preserving splenic hilar lymphadenectomy on the surgical outcome of proximal gastric cancer: a propensity score-matched, case-control study. *Surg Endosc* 2017;31:1383-1392.
[PUBMED](#) | [CROSSREF](#)